Consider applying to the Notice of Special Interest (NOSI): Research on Early Allergy Determinants Using Biosamples from the SUNBEAM Birth Cohort if you can propose studies that use available biologic and environmental samples collected as part of the birth cohort study Systems Biology of Early Atopy (SUNBEAM). The goal is to discover and advance the understanding of novel and established clinical, environmental, biological, and genetic early-life factors in the development of allergic diseases.
Studies using these samples are expected to give a deeper understanding of mechanisms contributing to the development of allergic diseases, disease endotypes, and will identify molecular targets for disease prevention.
Note: NIAID is soliciting only R01 applications through this NOSI.
Research areas of interest to this NOSI include, but are not limited to the following:
- Identification of biological pathways associated with the development of allergic disease (AD, FA, and respiratory allergy) in early life.
- Identification of endotypes of allergic disease (AD, FA, and respiratory allergy) in early life.
- Elucidation of microbial factors associated with the development of allergic disease (AD, FA, and respiratory allergy).
- Identification of biomarkers and biomarker-based models that predict the development of or indicate the presence of early allergic disease (AD, FA, and respiratory allergy).
- Understanding the role of early environmental exposures on the development of allergic disease (AD, FA, and respiratory allergy).
Do not propose any of the following topics as they are not supported under this NOSI:
- Assay development
- Collection of samples not already specified in the protocol
- Primary focus on clinical data and not on sample analyses
Be aware of the following:
- Studies proposed under this NOSI must adhere to guidelines that have been established by the SUNBEAM Steering Group for managing SUNBEAM samples.
- Potential applicants are highly encouraged to first communicate with the NIH scientific/research contact listed below to discuss the SUNBEAM sample management guidelines and sample availability.
- Applicants are strongly encouraged to establish an agreement with the SUNBEAM Steering Group prior to submission; a collaboration letter reflecting this agreement can be included as a letter of support. The NIH scientific/research contact will help establish communication between the applicant and the SUNBEAM Steering Group.
Application and Submission Information
This notice applies to due dates on or after October 5, 2023, and subsequent receipt dates through July 5, 2026.
Submit applications for this initiative using the following notice of funding opportunity (NOFO) or any reissues of this announcement through the expiration date of this notice: NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed).
All instructions in the SF 424 (R&R) Application Guide and the NOFO used for submission must be followed, with the following addition:
- For funding consideration, applicants must include “NOT-AI-23-058” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
For additional information, check Questions and Answers for Notice of Special Interest (NOSI)—Research on Early Allergy Determinants Using Biosamples from the SUNBEAM Birth Cohort for information about SUNBEAM, including the SUNBEAM protocol.
Contact Information
For inquiries, contact NIAID’s scientific/research contact Dr. Patricia C. Fulkerson at patricia.fulkerson@nih.gov or 202-641-4535.